MetaCap

Avita Medical Inc. (RCEL)

NASDAQ: RCELHealth CareMedical/Dental InstrumentsUSD

15.62-0.37 (-2.31%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RCEL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$494.96M
EPS (TTM)
-$1.17
52-week range
3.22 – 18.43
Day range
15.51 – 16.26
Volume / Avg
386.98K / 417.02K
Beta
—

52-week range

$3.22$18.43

RCEL stock today

Avita Medical (RCEL) closed at $15.62 on Nov 20, down 2.31% (-$0.37), versus the S&P 500's 3.70% decline. At this level, RCEL sits near the top of its 52-week range of $3.22 to $18.43: 15.2% below the high, set on Nov 9, 2026 and 385.1% above the low. RCEL is up 352.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 312.1%.

Avita Medical has posted a net loss over the last twelve months (EPS of -$1.17), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Avita Medical

Company profile

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2.

Industry
Medical/Dental Instruments
CEO
Mr. Cary G. Vance
Headquarters
Valencia, CA
Employees
226

Financial highlights

Full financials

In fiscal 2025, Avita Medical generated $71.6 million in revenue, up 11.5% from fiscal 2024, its 7th consecutive year of revenue growth. Avita Medical reported a net loss of $48.6 million, compared with a loss of $61.8 million a year earlier. Gross margin was 82.1% (down from 85.8%) and operating margin -59.4%.

Avita Medical annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$71.61M$64.25M$50.14M$34.42M$29.23M
Growth+11.45%+28.14%+45.68%+17.75%+104.95%
Net income$-48.59M$-61.84M$-35.38M$-26.66M$-26.58M
EPS (diluted)$-1.74$-2.39$-1.40$1.07$1.17

Analyst forecast

Forecast

Consensus (3 analysts)

strong_buy

Avg. price target

$20.69+32.46%

  • Strong buy 0
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $19.64High $21.82

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.20 vs —

RCEL news

All RCEL news

Avita Medical peers

Health Care sector
RCEL peer companies
CompanyPrice% ChgMarket capCompare
CARLCarlsmed Inc.17.42+1.16%$477.38Mvs RCEL
ANGOAngioDynamics Inc.10.81+0.46%$454.61Mvs RCEL
MDXGMiMedx Group Inc3.05-1.93%$445.07Mvs RCEL
SENSSenseonics Holdings Inc.8.02-9.94%$439.34Mvs RCEL
SGHTSight Sciences Inc.10.18-4.14%$565.79Mvs RCEL
SIShoulder Innovations Inc.20.15-0.79%$421.58Mvs RCEL
TCMDTactile Systems Technology Inc.25.60-1.50%$573.48Mvs RCEL
MOBIMobia Medical Inc.11.85-0.08%$394.50Mvs RCEL

Indexes, lists and sector

Avita Medical stock FAQ

What is Avita Medical's stock price today?

RCEL last traded at $15.62 as of Nov 20, 4:00 PM EST, down 2.31% on the day. Prices are delayed at least 15 minutes.

Does Avita Medical pay a dividend?

No. Avita Medical does not currently pay a regular cash dividend.

Who is Avita Medical's CEO?

Mr. Cary G. Vance is the chief executive officer of Avita Medical Inc., which has about 226 employees.

Has RCEL ever split its stock?

Yes. The most recent RCEL stock split was a 1-for-5 split on Jun 30, 2020.

What is the RCEL 52-week high?

The 52-week high for RCEL is $18.43 and the 52-week low is $3.22. The stock is currently 15.2% below its high.

Compare RCEL